Barasertib (AZD1152-HQPA)

For research use only.

Catalog No.S1147 Synonyms: AZD2811

80 publications

Barasertib (AZD1152-HQPA) Chemical Structure

CAS No. 722544-51-6

Barasertib (AZD1152-HQPA, AZD2811) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 387 In stock
USD 670 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Barasertib (AZD1152-HQPA) has been cited by 80 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Barasertib (AZD1152-HQPA, AZD2811) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Targets
Aurora B [1]
(Cell-free assay)
0.37 nM
In vitro

AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying ~100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP NWLuRVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjjNE02ODBibl2= M3fPbVQ5yqCq M4LsNmlEPTB;MkWgcm0> Mof6NlUzPzd4NUm=
LNCaP MVTBdI9xfG:|aYOgRZN{[Xl? NVXPXpk4OC13MECgcm0> MmewOFjDqGh? NUHWfXczcW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cCC2aILveYdpKGOjc4Dhd4UuOyC3cILl[5Vt[XSrb36= NGTydYkzPTJ5N{[1PS=>
LNCaP MWfGeY5kfGmxbjDBd5NigQ>? NFHPeXk2OCCwTR?= MkLKOFghcA>? NY\kWHJucW6mdXPld{BucWO{b371Z4xmcSC5aYToJIFv\XWpZX7pZ{Bu\WOqYX7pd40> NUfGWGZLOjV{N{e2OVk>
Ramos M2TsVGZ2dmO2aX;uJGF{e2G7 NHTsfXY2ODBibl2= M2\mUFAuPzJiaB?= MoT6bY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn NYrvR|BDOjF|N{G0OFY>
Daudi  NFH0V3VHfW6ldHnvckBCe3OjeR?= MXy1NFAhdk1? Ml;TNE04OiCq Mlq3bY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn MUSyNVM4OTR2Nh?=
L540 NYTUd4x6TnWwY4Tpc44hSXO|YYm= M4H6RVUxOCCwTR?= MkWwNE04OiCq NUDsPJd3cW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl NHu0TmQzOTN5MUS0Oi=>
BJAJ NF;yXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPVOVAxKG6P NVvM[4x6OC15MjDo NIHsbW1qdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NWHPfYN4OjF|N{G0OFY>
Ramos M1ixSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\XTGs2ODBibl2= M1PaWlAuPzJiaB?= NVLlfItXcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> M4iz[FIyOzdzNES2
Raji NF7yV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;qfVUxOCCwTR?= MnXONE04OiCq M4rmNIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= NVvIZm16OjF|N{G0OFY>
Daudi  M1zKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrlemM2ODBibl2= MWmwMVczKGh? NH7QdGFqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 Mlf4NlE{PzF2NE[=
L428 M{PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhdVUxOCCwTR?= MlK0NE04OiCq M4qxOIlvcGmkaYTzJINmdGxiZ4Lve5Rp MWmyNVM4OTR2Nh?=
KM-H2 NUfKbXpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW4OVAxKG6P MVqwMVczKGh? NV6ybIlIcW6qaXLpeJMh[2WubDDndo94fGh? M1vzeFIyOzdzNES2
HDLM-2 NH\pOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHjRpo2ODBibl2= MXqwMVczKGh? MkDhbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NFjVUGkzOTN5MUS0Oi=>
L450 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5V|UxOCCwTR?= NVGyW5k3OC15MjDo M13IdolvcGmkaYTzJINmdGxiZ4Lve5Rp MYmyNVM4OTR2Nh?=
BJAJ MkTpRZBweHSxc3nzJGF{e2G7 NGHUfXU2ODBibl2= NV;teIxZOC15MjDo NFfxU3lqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NWTuXmZoOjF|N{G0OFY>
Ramos NXLtOo43SXCxcITvd4l{KEG|c3H5 M2qybFUxOCCwTR?= NWXIVm5vOC15MjDo NInucnJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MVKyNVM4OTR2Nh?=
Raji NHvqdmhCeG:ydH;zbZMhSXO|YYm= NFTDXGg2ODBibl2= M{DVWlAuPzJiaB?= NUjobHdxcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NX3TPGpmOjF|N{G0OFY>
Daudi  M3XIN2Fxd3C2b4Ppd{BCe3OjeR?= NV;ZPZpqPTByIH7N NUDFTIREOC15MjDo NE[1ZlZqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MW[yNVM4OTR2Nh?=
L428 Ml\QRZBweHSxc3nzJGF{e2G7 MmSwOVAxKG6P MnLFNE04OiCq NWHDZZVrcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NX3CPWxtOjF|N{G0OFY>
KM-H2 M3TCcmFxd3C2b4Ppd{BCe3OjeR?= MV21NFAhdk1? M1LuRVAuPzJiaB?= MnHObY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NIDKVYEzOTN5MUS0Oi=>
HDLM-2 MX;BdI9xfG:|aYOgRZN{[Xl? NWK4R2w4PTByIH7N MoP2NE04OiCq M3;jUIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NX:1V5dROjF|N{G0OFY>
L450 M{G2emFxd3C2b4Ppd{BCe3OjeR?= NELxVJk2ODBibl2= MnToNE04OiCq NUjoeZB3cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M2XqNlIyOzdzNES2
SW620 NFPuc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr5VmlITUN3ME2xNOKyOi5zIH7N NYKzSohLOjF{NEWwPVA>
HCT116 M2XtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTGNHJPTUN3ME2xNeKyOy5|IH7N M4XYe|IyOjR3MEmw
MDA-MB-435 NWj6cJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XZNFAuOTByMECgcm0> Mk\BNk02KGR? M4nBZmROW09? NECwZpNKSzVyPUGyOUBvVQ>? MU[yNFE4PTl{Nh?=
MDA-MB-468 NGjlOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1uxTlAuOTByMECgcm0> NUPlbmlUOi13IHS= M2DjcmROW09? Mn3vTWM2OD1zNDDuUS=> NF\pS|YzODF5NUmyOi=>
MDA-MB-231 NH7aVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTIOYExNTFyMECwJI5O MXqyMVUh\A>? NX3RfolYTE2VTx?= NXr1TWk4UUN3ME2xNFUhdk1? MmfXNlAyPzV7Mk[=
BT474 M1;TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnWd|F2OC1zMECwNEBvVQ>? M3vJZVIuPSCm NYXxcpFMTE2VTx?= NU[yWJlDUUN3ME24JI5O MXSyNFE4PTl{Nh?=
MDA-MB-361 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrSfY4xNTFyMECwJI5O NU\ITm9ROi13IHS= M1nWcWROW09? MkTnTWM2OD15MDDuUS=> MY[yNFE4PTl{Nh?=
HER18 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnVO5F6OC1zMECwNEBvVQ>? NEHzVFczNTViZB?= M{TqTWROW09? MXnJR|UxRTJyIH7N M{DwPVIxOTd3OUK2
HER18 NFLZPGpCeG:ydH;zbZMhSXO|YYm= M2L3dlExOCCwTR?= NVe4fXV[OC9{ND:0PEBp M2TaN2ROW09? MVHpcoR2[2W|IHHwc5B1d3OrczDhcoQhemWmdXPld{BkdG:wb3flcolkKHCxdHXueIlidA>? MVyyNFE4PTl{Nh?=
MDA-MB-231 NES5cWRCeG:ydH;zbZMhSXO|YYm= Ml;ZNVA2KG6P Mle2NE8zPC92ODDo M3vt[2ROW09? NVL1SpZCcW6mdXPld{BieG:ydH;zbZMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDwc5RmdnSrYXy= M4XQNVIxOTd3OUK2
JHH-1 M2\t[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S4d|AvO+LCk{GwNFDDqG6P M{\2[lczKGh? MorrSWM2OD1zNz60xtEyNjBibl2= MV6xPVkyOzl|NR?=
JHH-2 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjWNE4{6oDVMUCwNOKhdk1? NFj0dVc4OiCq MVPFR|UxRTJzOD6wxtEyOC56IH7N M{PBdFE6QTF|OUO1
JHH-4 NHXTUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj4eW0xNjQkgKOxNFAxyqCwTR?= NXXzT2NtPzJiaB?= NEXIWndGSzVyPUG1OU43yrFzNj64JI5O M3PqUFE6QTF|OUO1
HuH-1 M{DJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\kc5MxNjQkgKOxNFAxyqCwTR?= NIPacFE4OiCq M4jK[2VEPTB;MkeuN:KyPS5yIH7N MnLQNVk6OTN7M{W=
HuH-6 NFjHOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMlPjiJNzMECwxsBvVQ>? MUW3NkBp MmDaSWM2OD1|LkhCtVAvPiCwTR?= NHfTXVMyQTlzM{mzOS=>
HuH-7 M4fLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G5XFAvO+LCk{GwNFDDqG6P MYW3NkBp M{m1O2VEPTB;Nj64xtExNjNibl2= NV7yNm9YOTl7MUO5N|U>
HLE NXzwXmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nxVlAvO+LCk{GwNFDDqG6P MkD2O|IhcA>? NIrU[3hGSzVyPUS1MlnDuTZwNDDuUS=> NV[zTY9xOTl7MUO5N|U>
HLF MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLVdmExNjQkgKOxNFAxyqCwTR?= MUG3NkBp M2H5d2VEPTB;MUK2MlHDuTF{LkKgcm0> NUX2cmJOOTl7MUO5N|U>
PLC/PRF/5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX5PGkxNjQkgKOxNFAxyqCwTR?= Mnr5O|IhcA>? M2PFOGVEPTB;N{[uPeKyQS57IH7N MVmxPVkyOzl|NR?=
SK-Hep1 NEHVR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlPjiJNzMECwxsBvVQ>? MWK3NkBp NXfTXpNDTUN3ME2yNU46yrFzLkKgcm0> MV6xPVkyOzl|NR?=
Hep3B M3TvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfhO2Q4OC5|4pETNVAxOMLibl2= M4fIVlczKGh? Mn7MSWM2OD15LkdCtVEvOiCwTR?= MXOxPVkyOzl|NR?=
HepG2 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmwMlPjiJNzMECwxsBvVQ>? NXX1Uop4PzJiaB?= M3TKdGVEPTB;MUSuO:KyOS55IH7N M1SwTVE6QTF|OUO1
Ramos M3TMN2Fxd3C2b4Ppd{BCe3OjeR?= NGnuRoszPS93MD:xNFAhdk1? NWfRd5R[PDhiaB?= NHnr[m9qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> M2qwcFE6QDJ|MU[4
Daudi  MnflRZBweHSxc3nzJGF{e2G7 NYGzVVVMOjVxNUCvNVAxKG6P Mlr4OFghcA>? NVrST|Z7cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{ M4\aS|E6QDJ|MU[4
BALM-14 NU\1VHJ1SXCxcITvd4l{KEG|c3H5 NFXvUZMyOi53L{K1M|UxKG6P NXnCOHRoPDhiaB?= MoS3bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz MorPNVk5OjNzNki=
BALM-27 MYHBdI9xfG:|aYOgRZN{[Xl? M1[zXFEzNjVxMkWvOVAhdk1? MW[0PEBp NF3oSpVqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> MUGxPVgzOzF4OB?=
NB4 NW\5XGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrHS5ZqOC5yMT:wMlEwOSEQvF2= Mo[1OFghcA>? NGDRZ4pqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NVrsdlZ5OTh|Nke0PFQ>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN; 

PubMed: 26497213     


Downstream effects of barasertib-induced AURKB inhibition on histone H3 phosphorylation and TP53 protein levels in IMR5 and SK-N-BE (2c) as indicated after 24h (left) and 48h (right). TP53 and its downstream effector CDKN1A were up-regulated by barasertib䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

p53 / p21 / p-p38 / p38 ; 

PubMed: 24782314     


U2OS cells were treated with 50 nm or 100 nm AZD1152 for 24 h. p21, p38, p-p38, and p53 levels were determined by immunoblotting β-actin served as a loading control.

26497213 24782314
Immunofluorescence
p21 ; 

PubMed: 24782314     


U2OS cells were treated as in H. Levels of p21 were analyzed by immunostaining. DNA was counterstained with Hoechst 33258.

24782314
Growth inhibition assay
Cell viability ; 

PubMed: 26497213     


Dose response curves to barasertib at 72h of incubation normalized to the DMSO control sample (mean ± SD, n = 5). The inset depicts the normalized AUCs of each response curve. 

26497213
In vivo Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells. [1] In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1, and K562 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 24 or 48 hours
  • Method: Cells are exposed to various concentrations of AZD1152 for 24 or 48 hours. Cell proliferation is measured by 3H-thymidine uptake (isotope added 6 hours before harvest), and the concentration that induced 50% growth inhibition (IC50) is calculated from dose-response curves. Cell cycle analysis is performed by flow cytometry. Cell apoptosis is measured by annexin V–FITC apoptosis detection kit.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female immune-deficient BALB/c nude mice subcutaneously injected with MOLM13 cells
  • Dosages: 5 or 25 mg/kg
  • Administration: Intraperitoneal injection 4 times a week or every another day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.96 mM)
Ethanol 3 mg/mL (5.91 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.56
Formula

C26H30FN7O3

CAS No. 722544-51-6
Storage powder
in solvent
Synonyms AZD2811
Smiles CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

  • Answer:

    S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) supplier | purchase Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) cost | Barasertib (AZD1152-HQPA) manufacturer | order Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID